CoChat

Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

The Aurora A inhibitor alisertib shows encouraging activities in clinical trials against advanced breast cancer. However, it remains unclear whether and how the inflammatory microenvironment is involved in its efficacy. Here, we demonstrated that inhibition of Aurora A directly reshaped the immune microenvironment through removal of tumor-promoting myeloid cells and enrichment of anticancer T lymphocytes, which established a tumor-suppressive microenvironment and significantly contributed to the regression of murine mammary tumors. Mechanistically, alisertib treatment triggered apoptosis in myeloid-derived suppressor cells (MDSC) and macrophages, resulting in their elimination from tumors. Furthermore, alisertib treatment disrupted the immunosuppressive functions of MDSC by inhibiting Stat3-mediated ROS production. These alterations led to significant increases of active CD8+ and CD4+ T lymphocytes, which efficiently inhibited the proliferation of tumor cells. Intriguingly, alisertib combined with PD-L1 blockade showed synergistic efficacy in the treatment of mammary tumors. These results detail the effects of Aurora A inhibition on the immune microenvironment and provide a novel chemo-immunotherapy strategy for advanced breast cancers. Significance: These findings show that inhibition of Aurora A facilitates an anticancer immune microenvironment, which can suppress tumor progression and enhance anti–PD-L1 therapy in breast cancer. See related commentary by Rivoltini et al., p. 3169

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-18-3397

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Cited by

See all 102

Metadata

Authors
Yin, T., Zhao, Z.-B., Guo, J., Wang, T., Yang, J.-B., Wang, C., Long, J., Ma, S., Huang, Q., Zhang, K., Ma, X., Liu, C., Liu, S., Lian, Z.-X., & Yang, Z.
Affiliations
  • University of Science and Technology of China (CN)
  • 2Chronic Disease Laboratory, Institutes for Life Sciences and School of Medicine, South China University of Technology, Guangzhou, China.
  • South China University of Technology (CN)
  • Fudan University (CN)
Venue
Cancer Research
Published
2019-07-01
Volume
79
Issue
13
Pages
3431-3444
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2943638659
Cited by
92
References
50
Citations by year
2026: 10 · 2025: 9 · 2024: 14 · 2023: 17 · 2022: 8 · 2021: 17 · 2020: 13 · 2019: 4
FWCI
4.19
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Science and Technology (2015CB553804, 2014CB910602, 2017YFA0205600)
  • National Natural Science Foundation of China (31701178, 31571396, 31771498, 81430034, 91542123)
  • Scientific and Technological projects of Anhui province (1604a0802073)
  • Guangdong Introducing Innovative (2017ZT07S054)
  • Foundation of Hefei Center for Physical Science and Technology (2016FXCX004)
  • Medical Research Fund (WK9110000004)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
alisertib, breast cancer, myeloid-derived suppressor cells, tumor-associated macrophages, immunosuppression, PD-L1 blockade, tumor immune microenvironment, STAT3 signaling, reactive oxygen species, T cell activation, chemoimmunotherapy, combination therapy
MeSH terms
Animals, Breast Neoplasms, Humans, Myeloid Cells, Mice, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Aurora Kinase A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-3397
The paper
Yin, T., Zhao, Z.-B., Guo, J., Wang, T., Yang, J.-B., Wang, C., Long, J., Ma, S., Huang, Q., Zhang, K., Ma, X., Liu, C., Liu, S., Lian, Z.-X., & Yang, Z. (2019). Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-3397

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.